Imaxio, German Cancer Research Center deal

Imaxio granted the center an option to license rights to Imaxio’s IMX313 technology. DKFZ will evaluate IMX313’s ability to improve the efficacy of one of DKFZ’s HPV vaccines. Based on the results, the center may exercise its option to continue development. IMX313 is a small DNA sequence fused to an antigen gene. The IMX313 sequences auto-assemble into a heptamer when the fusion antigen is expressed as a recombinant protein, which presents the antigen seven times to the immune system. ...